877 related articles for article (PubMed ID: 12463477)
1. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
[TBL] [Abstract][Full Text] [Related]
2. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
3. Antigen-primed CD8+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing.
Komatsu M; Mammolenti M; Jones M; Jurecic R; Sayers TJ; Levy RB
Blood; 2003 May; 101(10):3991-9. PubMed ID: 12521999
[TBL] [Abstract][Full Text] [Related]
4. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
Marks L; Altman NH; Podack ER; Levy RB
Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
[TBL] [Abstract][Full Text] [Related]
5. The effect of the spleen on compartmental levels and distribution of donor progenitor cells after syngeneic and allogeneic bone marrow transplants.
Shatry AM; Jones M; Levy RB
Stem Cells Dev; 2004 Feb; 13(1):51-62. PubMed ID: 15068693
[TBL] [Abstract][Full Text] [Related]
6. Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis.
Jiang Z; Podack E; Levy RB
Blood; 2001 Jul; 98(2):390-7. PubMed ID: 11435308
[TBL] [Abstract][Full Text] [Related]
7. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function.
Baker MB; Riley RL; Podack ER; Levy RB
Proc Natl Acad Sci U S A; 1997 Feb; 94(4):1366-71. PubMed ID: 9037059
[TBL] [Abstract][Full Text] [Related]
8. A radio-resistant perforin-expressing lymphoid population controls allogeneic T cell engraftment, activation, and onset of graft-versus-host disease in mice.
Davis JE; Harvey M; Gherardin NA; Koldej R; Huntington N; Neeson P; Trapani JA; Ritchie DS
Biol Blood Marrow Transplant; 2015 Feb; 21(2):242-9. PubMed ID: 25459639
[TBL] [Abstract][Full Text] [Related]
9. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
[TBL] [Abstract][Full Text] [Related]
10. Photochemical treatment of donor lymphocytes inhibited their ability to facilitate donor engraftment or increase donor chimerism after nonmyeloablative conditioning or establishment of mixed chimerism.
Johnson BD; Taylor PA; Stankowski MC; Talib S; Hearst JE; Blazar BR
Biol Blood Marrow Transplant; 2002; 8(11):581-7. PubMed ID: 12463476
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation.
Reddy P; Teshima T; Hildebrandt G; Duffner U; Maeda Y; Cooke KR; Ferrara JL
Blood; 2002 Nov; 100(9):3429-31. PubMed ID: 12384449
[TBL] [Abstract][Full Text] [Related]
12. Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation.
Hanash AM; Levy RB
Blood; 2005 Feb; 105(4):1828-36. PubMed ID: 15494429
[TBL] [Abstract][Full Text] [Related]
13. Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice.
Baker MB; Podack ER; Levy RB
Biol Blood Marrow Transplant; 1995 Dec; 1(2):69-73. PubMed ID: 9118294
[TBL] [Abstract][Full Text] [Related]
14. A synthetic CD4-CDR3 peptide analog enhances bone marrow engraftment across major histocompatibility barriers.
Koch U; Korngold R
Blood; 1997 Apr; 89(8):2880-90. PubMed ID: 9108408
[TBL] [Abstract][Full Text] [Related]
15. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
16. Myelosuppressive conditioning is required to achieve engraftment of pluripotent stem cells contained in moderate doses of syngeneic bone marrow.
Tomita Y; Sachs DH; Sykes M
Blood; 1994 Feb; 83(4):939-48. PubMed ID: 7906567
[TBL] [Abstract][Full Text] [Related]
17. T-cell subsets mediate graft-versus-myeloid leukemia responses via different cytotoxic mechanisms.
Hsieh MH; Patterson AE; Korngold R
Biol Blood Marrow Transplant; 2000; 6(3):231-40. PubMed ID: 10871148
[TBL] [Abstract][Full Text] [Related]
18. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease.
Maeda Y; Levy RB; Reddy P; Liu C; Clouthier SG; Teshima T; Ferrara JL
Blood; 2005 Mar; 105(5):2023-7. PubMed ID: 15466930
[TBL] [Abstract][Full Text] [Related]
19. Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation.
Whartenby KA; Straley EE; Kim H; Racke F; Tanavde V; Gorski KS; Cheng L; Pardoll DM; Civin CI
Blood; 2002 Nov; 100(9):3147-54. PubMed ID: 12384412
[TBL] [Abstract][Full Text] [Related]
20. Murine gamma/delta-expressing T cells affect alloengraftment via the recognition of nonclassical major histocompatibility complex class Ib antigens.
Blazar BR; Taylor PA; Bluestone JA; Vallera DA
Blood; 1996 May; 87(10):4463-72. PubMed ID: 8639809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
